(VIANEWS) - TransGlobe Energy Corporation (TGA), Safe Bulkers (SB), Charles River Laboratories (CRL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. TransGlobe Energy Corporation (TGA)
36% sales growth and 19.88% return on equity
TransGlobe Energy Corporation, together with its subsidiaries, engages in the acquisition, exploration, development, and production of crude oil and natural gas in Egypt and Canada.
TransGlobe Energy Corporation's sales growth this year is expected to be 35.3% and 23.7% for next year.
Year-on-year quarterly revenue growth grew by 245.7%, now sitting on 159.82M for the twelve trailing months.
Volume
Today's last reported volume for TransGlobe Energy Corporation is 663058 which is 8.15% above its average volume of 613035.
TransGlobe Energy Corporation's sales growth for the next quarter is 36%. The company's growth estimates for the ongoing quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.88%.
Volatility
TransGlobe Energy Corporation's last day, last week, and last month's current intraday variation average was 2.10%, 3.41%, and 2.91%, respectively.
TransGlobe Energy Corporation's highest amplitude of average volatility was 7.41% (day), 6.94% (last week), and 6.04% (last month), respectively.
TransGlobe Energy Corporation's Stock Yearly Top and Bottom Value
TransGlobe Energy Corporation's stock is valued at $3.65 at 15:22 EST, way below its 52-week high of $4.08 and way above its 52-week low of $1.38.
TransGlobe Energy Corporation's Moving Average
TransGlobe Energy Corporation's worth is way above its 50-day moving average of $3.19 and way higher than its 200-day moving average of $2.44.2. Safe Bulkers (SB)
19.3% sales growth and 21.73% return on equity
Safe Bulkers, Inc. provides marine drybulk transportation services.
Safe Bulkers's sales growth this year is expected to be 62.8% and a negative 0.4% for next year.
Year-on-year quarterly revenue growth grew by 78.1%, now sitting on 288.82M for the twelve trailing months.
Volume
Today's last reported volume for Safe Bulkers is 1354620 which is 3.38% above its average volume of 1310320.
Safe Bulkers's sales growth for the next quarter is 19.3%. The company's growth estimates for the ongoing quarter and the next is 875% and 92.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.73%.
Volatility
Safe Bulkers's last day, last week, and last month's current intraday variation average was 0.47%, 3.08%, and 2.82%, respectively.
Safe Bulkers's highest amplitude of average volatility was 5.76% (day), 6.13% (last week), and 5.86% (last month), respectively.
Safe Bulkers's Stock Yearly Top and Bottom Value
Safe Bulkers's stock is valued at $4.22 at 15:22 EST, way below its 52-week high of $5.44 and way higher than its 52-week low of $2.12.
Safe Bulkers's Moving Average
Safe Bulkers's worth is way higher than its 50-day moving average of $3.74 and higher than its 200-day moving average of $3.93.3. Charles River Laboratories (CRL)
17.6% sales growth and 18.37% return on equity
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services.
Charles River Laboratories's sales growth this year is expected to be 22.2% and 11.9% for next year.
Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 3.43B for the twelve trailing months.
Volume
Today's last reported volume for Charles River Laboratories is 549213 which is 18.46% above its average volume of 463614.
Charles River Laboratories's sales growth for the next quarter is 17.6%. The company's growth estimates for the ongoing quarter and the next is 10.7% and 7.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.37%.
Volatility
Charles River Laboratories's last day, last week, and last month's current intraday variation average was 2.21%, 1.46%, and 1.82%, respectively.
Charles River Laboratories's highest amplitude of average volatility was 3.82% (day), 3.04% (last week), and 3.51% (last month), respectively.
Charles River Laboratories's Stock Yearly Top and Bottom Value
Charles River Laboratories's stock is valued at $278.00 at 15:22 EST, way below its 52-week high of $460.21 and way higher than its 52-week low of $237.27.
Charles River Laboratories's Moving Average
Charles River Laboratories's worth is way under its 50-day moving average of $393.86 and way below its 200-day moving average of $371.52.4. Entegris (ENTG)
16.5% sales growth and 26.45% return on equity
Entegris, Inc. develops, manufactures, and supplies microcontamination control products, specialty chemicals, and advanced materials handling solutions for manufacturing processes in the semiconductor and other high-technology industries in North America, Taiwan, South Korea, Japan, China, Europe, and Southeast Asia.
Entegris's sales growth this year is expected to be 16.9% and 12% for next year.
Year-on-year quarterly revenue growth grew by 22.7%, now sitting on 2.3B for the twelve trailing months.
Volume
Today's last reported volume for Entegris is 771740 which is 43.96% below its average volume of 1377300.
Entegris's sales growth for the next quarter is 16.5%. The company's growth estimates for the present quarter and the next is 41.4% and 20%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.45%.
Volatility
Entegris's last day, last week, and last month's current intraday variation average was 0.87%, 2.86%, and 3.33%, respectively.
Entegris's highest amplitude of average volatility was 4.31% (day), 5.81% (last week), and 5.12% (last month), respectively.
Entegris's Stock Yearly Top and Bottom Value
Entegris's stock is valued at $133.34 at 15:22 EST, way below its 52-week high of $158.00 and way above its 52-week low of $93.50.
Entegris's Moving Average
Entegris's worth is higher than its 50-day moving average of $130.38 and higher than its 200-day moving average of $127.31.5. Pan American Silver Corp. (PAAS)
14.2% sales growth and 9.94% return on equity
Pan American Silver Corp., together with its subsidiaries, engages in the exploration, development, extraction, processing, refining, and reclamation of silver, gold, zinc, lead, and copper mines in Canada, Mexico, Peru, Argentina, and Bolivia.
Pan American Silver Corp.'s sales growth this year is expected to be 29.4% and 22.1% for next year.
Year-on-year quarterly revenue growth grew by 53.2%, now sitting on 1.64B for the twelve trailing months.
Volume
Today's last reported volume for Pan American Silver Corp. is 3868680 which is 53.93% above its average volume of 2513210.
Pan American Silver Corp.'s sales growth for the next quarter is 14.2%. The company's growth estimates for the present quarter and the next is 11.8% and negative -24.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.94%.
Volatility
Pan American Silver Corp.'s last day, last week, and last month's current intraday variation average was 8.93%, 3.72%, and 2.59%, respectively.
Pan American Silver Corp.'s highest amplitude of average volatility was 8.83% (day), 6.14% (last week), and 4.28% (last month), respectively.
Pan American Silver Corp.'s Stock Yearly Top and Bottom Value
Pan American Silver Corp.'s stock is valued at $25.74 at 15:22 EST, way below its 52-week high of $36.14 and way higher than its 52-week low of $20.74.
Pan American Silver Corp.'s Moving Average
Pan American Silver Corp.'s worth is higher than its 50-day moving average of $23.51 and under its 200-day moving average of $26.11.6. 1-800-FLOWERS.COM (FLWS)
9.2% sales growth and 16.94% return on equity
1-800-FLOWERS.COM, Inc., together with its subsidiaries, provides gifts for various occasions in the United States and internationally.
1-800-FLOWERS.COM's sales growth this year is anticipated to be 7.3% and 7.7% for next year.
Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 2.21B for the twelve trailing months.
Volume
Today's last reported volume for 1-800-FLOWERS.COM is 744758 which is 29.35% below its average volume of 1054250.
1-800-FLOWERS.COM's sales growth is a negative 0% for the present quarter and 9.2% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 1350% and negative -90%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.94%.
Volatility
1-800-FLOWERS.COM's last day, last week, and last month's current intraday variation average was 1.75%, 4.30%, and 5.13%, respectively.
1-800-FLOWERS.COM's highest amplitude of average volatility was 4.74% (day), 7.36% (last week), and 7.13% (last month), respectively.
1-800-FLOWERS.COM's Stock Yearly Top and Bottom Value
1-800-FLOWERS.COM's stock is valued at $15.15 at 15:22 EST, way under its 52-week high of $38.66 and way above its 52-week low of $13.16.
1-800-FLOWERS.COM's Moving Average
1-800-FLOWERS.COM's worth is way below its 50-day moving average of $20.04 and way under its 200-day moving average of $28.83.7. Royalty Pharma (RPRX)
6.2% sales growth and 15.4% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma's sales growth this year is expected to be 5.6% and 3.5% for next year.
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 2.29B for the twelve trailing months.
Volume
Today's last reported volume for Royalty Pharma is 1255050 which is 22.83% below its average volume of 1626390.
Royalty Pharma's sales growth for the next quarter is 6.2%. The company's growth estimates for the current quarter and the next is 41.7% and 171.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.4%.
Volatility
Royalty Pharma's last day, last week, and last month's current intraday variation average was 0.21%, 1.26%, and 1.41%, respectively.
Royalty Pharma's highest amplitude of average volatility was 2.07% (day), 2.41% (last week), and 2.40% (last month), respectively.
Royalty Pharma's Stock Yearly Top and Bottom Value
Royalty Pharma's stock is valued at $38.42 at 15:22 EST, way under its 52-week high of $53.23 and way above its 52-week low of $34.86.
Royalty Pharma's Moving Average
Royalty Pharma's worth is below its 50-day moving average of $38.89 and below its 200-day moving average of $40.64.Previous days news about Royalty Pharma(RPRX)
- Hopeful golden cross forms on royalty pharma's chart. According to Benzinga on Tuesday, 1 March, "If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). "